[ESWL in hemophilia B].
One of the most dramatic dangers in treating nephrolithiasis by ESWL is the development of intra- and perirenal bleeding, which requires therapeutic intervention. Even in patients whose blood parameters suggest they are healthy, hematomas are found in up to 80%. Therefore, ESWL must be regarded as contraindicated in patients with blood disorders. A case of a patient suffering from hemophilia B and from a large renal pelvic stone is reported, whom we treated by ESWL twice after sufficient substitution. X-ray revealed that the patient was stone-free on the 25th day after the first ESWL session. ESWL. A review of the literature is presented.
Schlick
R
R
Klinik für Urologie, Medizinische Hochschule Hannover.
Djamilian
M
M
de Riese
W
W
Truss
M
M
Allhoff
E P
EP
Jonas
U
U
D000328:Adult; D000075202:Contraindications; D005164:Factor IX / Q000627:therapeutic use; D002836:Hemophilia B / Q000097:blood / Q000150:complications*; D006801:Humans; D007669:Kidney Calculi / Q000097:blood / Q000150:complications* / Q000628:therapy; D008096:Lithotripsy; D008297:Male; D010314:Partial Thromboplastin Time; D011292:Premedication; D012307:Risk Factors
D005164:Factor IX
ESWL bei Hämophilie B.